More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs.

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

U.S.-listed shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are up 3.5% premarket, following a bull note ...

JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...